Cis-platinum ototoxicity: clinical experience and temporal bone histopathology.
A clinical and pathologic study of cis-platinum ototoxicity was performed. Twenty-four patients treated with cis-platinum for head and neck cancer were studied prospectively. Post cis-platinum hearing losses were subclinical, detected in 25% of patients, isolated to 4 and 8 kHz, and did not exceed 25 dB at any frequency. Temporal bones from a 9-year-old with frontal lobe astrocytoma and with cis-platinum ototoxicity were studied with routine and special techniques to elucidate oto and neurotoxicity. Degenerative changes in the outer hair cells in the lower turns of the cochlea, in the spiral ganglion, and cochlear nerve were the most striking findings.
D000328:Adult; D000368:Aged; D001299:Audiometry; D002648:Child; D002945:Cisplatin / Q000009:adverse effects*; D003051:Cochlea / Q000473:pathology; D003056:Cochlear Nerve / Q000473:pathology; D005260:Female; D006311:Hearing Disorders / Q000139:chemically induced*; D034381:Hearing Loss / Q000175:diagnosis / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009925:Organ of Corti / Q000473:pathology; D013701:Temporal Bone / Q000473:pathology*
D002945:Cisplatin